![Logo for Monte Rosa Therapeutic Inc](/_next/image?url=https%3A%2F%2Ffiles.quartr.com%2Fcompany-logos%2F38316-2024-07-03-07-25-38.png&w=256&q=100)
Monte Rosa Therapeutic Investor Relations Material
Latest events
![Logo for Monte Rosa Therapeutic Inc](/_next/image?url=https%3A%2F%2Ffiles.quartr.com%2Fcompany-logos%2F38316-2024-07-03-07-25-38.png&w=128&q=100)
Study Result
Monte Rosa Therapeutic
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies
Latest reports from Monte Rosa Therapeutic Inc
Access all reports
Monte Rosa Therapeutics Inc. is a clinical-stage biotechnology company focused on developing molecular glue degraders (MGDs). These small molecules are designed to selectively degrade disease-causing proteins by harnessing the body’s natural protein degradation processes. The company targets a range of therapeutic areas, including oncology, autoimmune, and inflammatory diseases. Monte Rosa utilizes its proprietary QuEEN platform, which integrates proteomics, structural biology, AI, and machine learning, to rapidly identify and develop highly selective protein degraders. The company operates out of Boston, Massachusetts, with additional research facilities in Basel, Switzerland. Its shares trade on the NASDAQ.
Key slides for Monte Rosa Therapeutic Inc
![MRT - 2359 : Treatme](/_next/image?url=https%3A%2F%2Fcdn.quartr.com%2Fimages%2Fconference-calls%2Fmonte-rosa-therapeutic-inc-study-result-59e007a212157df8%2F14.png&w=3840&q=75)
![Logo for Monte Rosa Therapeutic Inc](/_next/image?url=https%3A%2F%2Ffiles.quartr.com%2Fcompany-logos%2F38316-2024-07-03-07-25-38.png&w=128&q=100)
Study Result
Monte Rosa Therapeutic Inc
![10
MRT - 2359-001](/_next/image?url=https%3A%2F%2Fcdn.quartr.com%2Fimages%2Fconference-calls%2Fmonte-rosa-therapeutic-inc-study-result-59e007a212157df8%2F10.png&w=3840&q=75)
![Logo for Monte Rosa Therapeutic Inc](/_next/image?url=https%3A%2F%2Ffiles.quartr.com%2Fcompany-logos%2F38316-2024-07-03-07-25-38.png&w=128&q=100)
Study Result
Monte Rosa Therapeutic Inc
Latest articles
![Key](/_next/image?url=https%3A%2F%2Fa.storyblok.com%2Ff%2F182663%2F2000x1125%2Fbbbaafadba%2Fpontis-dackmo_strong-opinions-loosely-held.png&w=3840&q=75)
Strong Opinions, Loosely Held: Pontus Dackmo on Flexibility and Market Psychology
After a two-decade career in finance, Pontus Dackmo co-founded Protean Funds Scandinavia in 2022, where he now serves as CEO and Investment Manager.
4 Sep 2024
![Key](/_next/image?url=https%3A%2F%2Fa.storyblok.com%2Ff%2F182663%2F2000x1125%2F7455f6afd1%2Fnovo-nordisk_the-danish-pharmaceutical-titan.png&w=3840&q=75)
Novo Nordisk: The Danish Pharmaceutical Titan Revolutionizing Global Healthcare
Novo Nordisk's rise to becoming Europe's largest company, reshaping global healthcare and Denmark's economy.
5 Sep 2024
![Key](/_next/image?url=https%3A%2F%2Fa.storyblok.com%2Ff%2F182663%2F2000x1125%2F5533bee49f%2Fthe-toyota-way.png&w=3840&q=75)
The Toyota Way: Revolutionizing Global Manufacturing
Explore how Toyota's Lean Manufacturing and Kaizen principles revolutionized production and quality, setting global benchmarks for excellence.
2 Sep 2024
Ticker symbol
GLUE
Country
🇺🇸 United States